Recap: Centogene Q3 Earnings

Shares of Centogene CNTG remained unaffected in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 97.88% year over year to ($0.30), which missed the estimate of ($0.28).

Revenue of $42,426,000 higher by 234.46% year over year, which beat the estimate of $28,350,000.

Guidance

Centogene hasn't issued any earnings guidance for the time being.

Centogene hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Dec 16, 2020

Time: 08:00 AM

ET Webcast URL: https://emea.directeventreg.com/der/validateConferenceId.action

Technicals

Company's 52-week high was at $28.71

Company's 52-week low was at $9.25

Price action over last quarter: Up 22.76%

Company Description

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.